Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Cash: 2013-2024

Historic Change in Cash for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$15.3 million.

  • Aclaris Therapeutics' Change in Cash fell 100.59% to -$146,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 360.07%. This contributed to the annual value of -$15.3 million for FY2024, which is 183.53% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Change in Cash of -$15.3 million as of FY2024, which was down 183.53% from -$5.4 million recorded in FY2023.
  • Aclaris Therapeutics' Change in Cash's 5-year high stood at $17.9 million during FY2022, with a 5-year trough of -$15.3 million in FY2024.
  • Moreover, its 3-year median value for Change in Cash was -$5.4 million (2023), whereas its average is -$926,333.
  • In the last 5 years, Aclaris Therapeutics' Change in Cash surged by 239.16% in 2022 and then slumped by 183.53% in 2024.
  • Aclaris Therapeutics' Change in Cash (Yearly) stood at -$13.9 million in 2020, then spiked by 138.10% to $5.3 million in 2021, then skyrocketed by 239.16% to $17.9 million in 2022, then tumbled by 130.11% to -$5.4 million in 2023, then tumbled by 183.53% to -$15.3 million in 2024.